Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Kyungheedae-ro 26, Dongdaemun-gu, Seoul, 02447, Republic of Korea.
Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Kyungheedae-ro 26, Dongdaemun-gu, Seoul, 02447, South Korea.
BMC Complement Altern Med. 2018 Jul 13;18(1):215. doi: 10.1186/s12906-018-2280-z.
Jawoongo is an herbal mixture used in traditional medicine to treat skin diseases. This study aimed to investigate whether Jawoongo ameliorates Atopic dermatitis (AD)-like pathology in mice and to understand its underlying cellular mechanisms.
AD was induced by 2, 4-Dinitrocholrlbenzene (DNCB) in BALB/c mice. Treatment with Jawoongo was assessed to study the effect of Jawoongo on AD in mice. Histological Analysis, blood analysis, RT-PCR, western blot analysis, ELISA assay and cell viability assay were performed to verify the inhibitory effect of Jawoongo on AD in mice.
We found that application of Jawoongo in an ointment form on AD-like skin lesions on DNCB-exposed BALB/c mice reduced skin thickness and ameliorated skin infiltration with inflammatory cells, mast cells and CD4+ cells. The ointment also reduced the mRNA levels of IL-2, IL-4, IL-13 and TNF-α in the sensitized skin. Leukocyte counts and the levels of IgE, IL-6, IL-10 and IL-12 were decreased in the blood of the DNCB-treated mice. Furthermore, studies on cultured cells demonstrated that Jawoongo exhibits anti-inflammatory activities, including the suppression of proinflammatory cytokine expression, nitric oxide (NO) production, and inflammation-associated molecule levels in numerous types of agonist-stimulated innate immune cell, including human mast cells (HMC-1), murine macrophage RAW264.7 cells, and splenocytes isolated from mice.
These findings indicate that Jawoongo alleviates DNCB-induced AD-like symptoms via the modulation of several inflammatory responses, indicating that Jawoongo might be a useful drug for the treatment of AD.
Jawoongo 是一种草药混合物，用于传统医学治疗皮肤病。本研究旨在探讨 Jawoongo 是否能改善小鼠的特应性皮炎（AD）样病理，并了解其潜在的细胞机制。
通过 2,4-二硝基氯苯（DNCB）在 BALB/c 小鼠中诱导 AD。评估 Jawoongo 的治疗效果，以研究 Jawoongo 对小鼠 AD 的影响。进行组织学分析、血液分析、RT-PCR、western blot 分析、ELISA 测定和细胞活力测定，以验证 Jawoongo 对小鼠 AD 的抑制作用。
我们发现，将 Jawoongo 以软膏形式应用于 DNCB 暴露的 BALB/c 小鼠的 AD 样皮肤损伤上，可减少皮肤厚度并改善炎症细胞、肥大细胞和 CD4+细胞的皮肤浸润。软膏还降低了致敏皮肤中 IL-2、IL-4、IL-13 和 TNF-α 的 mRNA 水平。DNCB 处理小鼠的白细胞计数和 IgE、IL-6、IL-10 和 IL-12 水平降低。此外，对培养细胞的研究表明，Jawoongo 具有抗炎活性，包括抑制多种激动剂刺激的固有免疫细胞（包括人肥大细胞[HMC-1]、鼠巨噬细胞 RAW264.7 细胞和从小鼠分离的脾细胞）中促炎细胞因子表达、一氧化氮（NO）产生和炎症相关分子水平。
这些发现表明，Jawoongo 通过调节几种炎症反应缓解 DNCB 诱导的 AD 样症状，表明 Jawoongo 可能是治疗 AD 的有用药物。
